about
Clinical studies in lysosomal storage diseases: Past, present, and futurePediatric Sepsis Biomarker Risk Model-II: Redefining the Pediatric Sepsis Biomarker Risk Model With Septic Shock Phenotype.Using genetics to enable studies on the prevention of Alzheimer's diseaseGenetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study.Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendationsGenome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis.Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience.Adaptive trial designs: a review of barriers and opportunitiesRisk Stratification and Prognosis in Sepsis: What Have We Learned from Microarrays?Association of elevated urinary concentration of renin-angiotensin system components and severe AKI.Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine.Individualization of drug therapy: history, present state, and opportunities for the future.Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.Bioinformatics advances for clinical biomarker development.Evaluating biomarkers for prognostic enrichment of clinical trials.Genetic biomarkers of placebo response: what could it mean for future trial design?Comparison of effect sizes between enriched and nonenriched trials of analgesics for chronic musculoskeletal pain: a systematic review.Remarks on designs enriching for placebo non-responders.Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke.Development of biomarker combinations for postoperative acute kidney injury via Bayesian model selection in a multicenter cohort study.The plan of enrichment designs for dealing with high placebo response.Is this the dose for you?: the role of modeling.Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
P2860
Q27025186-E122D9FC-E6AB-424D-BC93-2B6D82313797Q33434503-FDC2AA68-336A-4BCA-A5DF-3137EA3B474FQ34038890-3C9296CC-03F0-455C-B26B-FC3E3AB62DC5Q34273354-529A5EAA-D7B7-4200-B960-FF5286369BAAQ35796544-50066628-BF96-409D-80E8-A0A9A8FE607AQ35846608-70F508E1-6A56-4767-9D0C-4EC3286C187EQ35932980-4B3B3985-EA32-4E01-92C6-3D24694168E5Q36129605-FB4FEDC8-BC14-4BB1-A165-C3CD842B7F0CQ36460054-5A398E3C-0931-4CAC-9CC5-CFB0B894E1CFQ36945095-39767A4A-2710-4CBB-AF55-1BA774948514Q37359056-9C09A02F-1DDC-4941-9CF9-EE16A8076DC2Q37959013-194EF1B0-F3CF-42E7-9749-3B307D90E1BCQ38040697-BDA7A36E-0701-4512-AAF4-A3B8778133ACQ38068392-9512C8AB-7DCB-4438-8C49-A5B0DAC1FF5EQ38088378-70BBC3E7-B354-486D-9FDF-6B9C6C99704AQ38399183-150D19C4-E8C8-47AB-8CB0-BE7558AC39ECQ39347818-F3D1A186-0F73-412B-BBAF-58666327F672Q39388226-33D2F05B-ADCC-43E6-95BE-D2E55E24588EQ40107082-F692AFB7-6F98-4FAA-B738-EE9526DAF114Q40197692-0BD8CF20-502B-4EC8-92C1-DDFCFE34E9AFQ40675012-A0EA805B-F396-4484-B40F-C866B60F6FA0Q46158508-FB7319F0-3A4B-4D71-8B58-EA080750EAEEQ47384535-073432A4-91EF-4440-96E4-176CDC8F165DQ47653029-74A5E15B-3872-471E-8B48-6FDD010A43C9Q48377645-1F921F19-A1DE-41D7-B252-F21404682655Q53118219-35623589-5B42-4503-AE14-BFFDFE7C6D94Q56828560-FDAFA285-F011-4CD0-97FC-2CE9FA225859
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enrichment of clinical study populations.
@en
Enrichment of clinical study populations.
@nl
type
label
Enrichment of clinical study populations.
@en
Enrichment of clinical study populations.
@nl
prefLabel
Enrichment of clinical study populations.
@en
Enrichment of clinical study populations.
@nl
P2860
P356
P1476
Enrichment of clinical study populations.
@en
P2093
P2860
P304
P356
10.1038/CLPT.2010.233
P407
P577
2010-10-13T00:00:00Z